| Literature DB >> 31562531 |
Anneke Alkemade1, Gilles de Hollander2,3, Steven Miletic1, Max C Keuken1, Rawien Balesar1, Onno de Boer4, Dick F Swaab5, Birte U Forstmann6.
Abstract
The subthalamic nucleus (STN) is successfully used as a surgical target for deep brain stimulation in the treatment of movement disorders. Interestingly, the internal structure of the STN is still incompletely understood. The objective of the present study was to investigate three-dimensional (3D) immunoreactivity patterns for 12 individual protein markers for GABA-ergic, serotonergic, dopaminergic as well as glutamatergic signaling. We analyzed the immunoreactivity using optical densities and created a 3D reconstruction of seven postmortem human STNs. Quantitative modeling of the reconstructed 3D immunoreactivity patterns revealed that the applied protein markers show a gradient distribution in the STN. These gradients were predominantly organized along the ventromedial to dorsolateral axis of the STN. The results are of particular interest in view of the theoretical underpinning for surgical targeting, which is based on a tripartite distribution of cognitive, limbic and motor function in the STN.Entities:
Keywords: Basal ganglia; Immunocytochemistry; Neuroanatomy; Subthalamic nucleus
Mesh:
Substances:
Year: 2019 PMID: 31562531 PMCID: PMC6875153 DOI: 10.1007/s00429-019-01960-3
Source DB: PubMed Journal: Brain Struct Funct ISSN: 1863-2653 Impact factor: 3.270
Clinicopathological data
| NBB# | Age (y) | Sex | PMD (h:m) | Fix (days) | |
|---|---|---|---|---|---|
| 12-062 | 88 | M | 05:40 | Nd | |
| 12-082 | 101 | F | 05:10 | Nd | |
| 12-104 | 79 | M | 06:30 | Nd | |
| 13-095 | 101 | F | 06:15 | 57 | |
| 14-037 | 101 | F | 07:27 | 57 | |
| 14-051 | 92 | M | 07:45 | 57 | |
| 14-069 | 73 | M | 04:25 | 56 | |
| 15-033 | 93 | M | 07:40 | 59 | |
| 15-035 | 73 | M | 08:00 | 56 | |
| 15-055 | 72 | F | 06:50 | 55 |
AD Alzheimer’s disease, Fix fixation duration, Nd not determined, PTCA percutaneous transluminal coronary angioplasty, PMD postmortem delay, TIA transient ischemic attack, y years
aDetermined postmortem
Fig. 1Example of immunoreactivity in specimen #14-051 for serotonin transporter (SERT), calretinin (CALR), parvalbumin (PARV), tyrosine hydroxylase (TH), synaptophysin (SYN), transferrin (TF), glutamic acid decarboxylase (GAD65/67), neurofilament H (SMI32), ferritin (FERR), GABA receptor subunit A3 (GABRA3), vesicular glutamate transporter 1 (VGLUT1), myelin basic protein (MBP)
Fig. 2Example of a single STN (#15-033). Immunoreactivity is presented as maximum intensity Z-stacks, as well as consecutive sections for serotonin transporter (SERT), calretinin (CALR), parvalbumin (PARV), tyrosine hydroxylase (TH), synaptophysin (SYN), transferrin (TF), glutamic acid decarboxylase (GAD65/67), neurofilament H (SMI32), ferritin (FERR), GABA receptor subunit A3 (GABRA3), vesicular glutamate transporter 1 (VGLUT1), myelin basic protein (MBP). Note that the panels reflect immunoreactivity, not protein copies. Therefore, differences across markers cannot be interpreted as differences in protein expression levels
Preferred model specimens and protein marker defined as the model with the lowest BIC
| NBB# | CALR | FER | GABRA3 | GAD6567 | MBP | PARV | SERT | SMI32 | SYN | TH | TRANSF | VGLUT1 | Overall |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13-095 | B | B | D | B | D | D | C | B | D | B | D | B | B |
| 14-037 | B | B | B | B | B | B | B | B | D | D | B | D | B |
| 14-051 | B | D | B | B | D | D | B | B | D | B | D | B | B |
| 14-069 | B | B | B | B | D | B | B | C | C | C | C | D | B |
| 15-033 | B | B | B | B | B | B | B | B | B | B | B | B | B |
| 15-035 | B | C | D | B | B | D | B | D | B | B | B | C | B |
| 15-055 | B | B | D | B | D | D | B | D | D | D | B | D | D |
| Across specimens | B | B | B | B | D | D | B | B | D | B | B | B | B |
Model A represents homogenous immunoreactivity across the nucleus; Model B represents a linear gradient model; Model C assumes three subdivisions; Model D assumes a gradient of non-linear changes
Fig. 3Quality of fit for Model B (linear gradient) over the rostrocaudal axis of the STN. Top panels show the data, and bottom panels show the model. Colors represent overall mean normalized intensity for the data, and the model. Relative changes in immunoreactivity are indicated in colors, ranging from relatively low (blue) to high (red) expression levels. Note that protein marker expression was present throughout the entire STN, for each marker, with clear local intensity differences within markers
Primary antibody characteristics
| Primary Ab | Dilution | Protein | Function | Source | Specificity |
|---|---|---|---|---|---|
| Pilot studies | |||||
| NPY | 1:1,000 | Neuropeptide Y | Neurotransmitter, affects cortical excitability, stress response, food intake, circadian rhythms, and cardiovascular function | Niepke, NIN | IEF, preadsorptions, omission primary Ab, ICC (van der Beek et al. |
| CRH | 1:100,000 | Corticotropin-releasing hormone | Peptide hormone/neurotransmitter involved in the stress response | PFU83, Free University of Amsterdam | Preadsorptions, preimmune serum testing, omission primary Ab, ICC (Raadsheer et al. |
| ORXA | 1:20,000 | Orexin A | Peptide hormone involved in sleep regulation | H003-30, Phoenix Pharmaceuticals | Preadsorptions, dot blots, ICC (Fronczek et al. |
| VIP | 1:1,000 | Vasoactive intestinal peptide | Peptide hormone involved in circadian rhythmicity | Viper, NIN | IEF, preadsorptions, omission primary Ab, ICC (van der Beek et al. |
| Aromatase | 1:1,500 | Aromatase | Enzyme involved in estrogen synthesis | Narom, NIN | ICC (van der Beek et al. |
| ChAT | 1:200 | Choline acetyl transferase | Enzyme involved in acetylcholine synthesis | ICC (Dubelaar et al. | |
| Distribution studies | |||||
| SMI-32 | 1:2,000 | Neurofilament H | Major cytoskeletal component | SMI-32, Covance | ICC, WB (Bar-Peled et al. |
| SYN | 1:250 | Synaptophysin | Major synaptic vesicle protein | A0010, DAKO | ICC, WB, ELISA (Sager et al. |
| TH | 1:1,500 | Tyrosine hydroxylase | Rate-limiting enzyme in dopamine production (Nagatsu et al. | MAb318, Millipore | ICC, WB (Perez et al. |
| VGLUT1 | 1:10,000 | Vesicular glutamate transporter 1 | Sodium dependent phosphate transporter, glutamate signaling (Takamori et al. | 135302, Synaptic systems | ICC, WB (Kirvell et al. |
| GAD65/67 | 1:300 | Glutamate decarboxylase 65/67 | Enzyme that catalyzes glutamate to GABA conversion | Ab1511, Millipore | ICC, WB (Mori et al. |
| GABRA3 | 1:250 | GABA-A receptor subunit alpha 3 | Receptor subunit | AGA-003, Alomone Labs | ICC, WB (Caspary et al. |
| SERT | 1:5,000 | Serotonin transporter | Determines serotonin availability in the synaptic cleft (Bengel et al. | MAb5618, Millipore | ICC, WB (Bauman et al. |
| PARV | 1:2,500 | Parvalbumin | Calcium-binding protein | 195004, Synaptic systems | ICC (Andrioli et al. |
| CALR | 1:450 | Calretinin | Calcium binding protein | 6B3, Swant | ICC, WB (Schiffmann et al. |
| TRANSF | 1:4,000 | Transferrin | Iron-binding glycoprotein | Ab9538, Abcam | ICC, WB (Zawadzka et al. |
| FERR | 1:1,500 | Ferritin | Iron-binding protein expressed in oligodendrocytes (Vymazal et al. | sc-14416, Santa Cruz | ICC, WB (Saunders et al. |
Ab antibody, ELISA enzyme-linked immunosorbent assay, ICC immunocytochemistry, IEF isoelectric focusing, WB Western Blotting